Cargando…
Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B
AIMS: Assessing the diagnostic performances of APRI and FIB-4 using age as a categorical marker. METHODS: 822 chronic hepatitis B (CHB) patients were included. Using METAVIR scoring system as a reference, the performances of APRI and FIB-4 were compared between patients aged≥30 and patients aged<...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542225/ https://www.ncbi.nlm.nih.gov/pubmed/28514753 http://dx.doi.org/10.18632/oncotarget.17470 |
_version_ | 1783254946538323968 |
---|---|
author | Li, Qiang Lu, Chuan Li, Weixia Huang, Yuxian Chen, Liang |
author_facet | Li, Qiang Lu, Chuan Li, Weixia Huang, Yuxian Chen, Liang |
author_sort | Li, Qiang |
collection | PubMed |
description | AIMS: Assessing the diagnostic performances of APRI and FIB-4 using age as a categorical marker. METHODS: 822 chronic hepatitis B (CHB) patients were included. Using METAVIR scoring system as a reference, the performances of APRI and FIB-4 were compared between patients aged≥30 and patients aged<30 years. RESULTS: The APRI AUROC in patients aged<30 years was lower than that in patients aged≥30 years for significant fibrosis (0.61 vs 0.70, p<0.001) and cirrhosis (0.64 vs 0.78, p<0.001). The FIB-4 AUROC in patients aged<30 years was lower than that in patients aged≥30 years for significant fibrosis (0.57 vs 0.65, p<0.001) and cirrhosis (0.63 vs 0.72, p<0.001). Using specificity≥90%, the APRI cut-off in patients aged<30 years was lower than patients aged≥30 years for significant fibrosis (1.0 vs 1.2) and cirrhosis (1.2 vs 1.5). Using sensitivity≥90%, the APRI cut-off in patients aged<30 years was also lower than patients aged≥30 years for significant fibrosis (0.2 vs 0.4) and cirrhosis (0.3 vs 0.5). Using specificity≥90%, the FIB-4 cut-off in patients aged<30 years was lower than that in patients aged≥30 years for significant fibrosis (1.2 vs 2.1) and cirrhosis (1.4 vs 2.6). Using sensitivity≥90%, the FIB-4 cut-off in patients aged<30 years was also lower than that in patients aged≥30 years for significant fibrosis (0.5 vs 0.8) and cirrhosis (0.8 vs 1.2). CONCLUSIONS: Evaluation of the diagnostic performances of APRI and FIB-4 should take age into consideration. |
format | Online Article Text |
id | pubmed-5542225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-55422252017-08-07 Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B Li, Qiang Lu, Chuan Li, Weixia Huang, Yuxian Chen, Liang Oncotarget Research Paper AIMS: Assessing the diagnostic performances of APRI and FIB-4 using age as a categorical marker. METHODS: 822 chronic hepatitis B (CHB) patients were included. Using METAVIR scoring system as a reference, the performances of APRI and FIB-4 were compared between patients aged≥30 and patients aged<30 years. RESULTS: The APRI AUROC in patients aged<30 years was lower than that in patients aged≥30 years for significant fibrosis (0.61 vs 0.70, p<0.001) and cirrhosis (0.64 vs 0.78, p<0.001). The FIB-4 AUROC in patients aged<30 years was lower than that in patients aged≥30 years for significant fibrosis (0.57 vs 0.65, p<0.001) and cirrhosis (0.63 vs 0.72, p<0.001). Using specificity≥90%, the APRI cut-off in patients aged<30 years was lower than patients aged≥30 years for significant fibrosis (1.0 vs 1.2) and cirrhosis (1.2 vs 1.5). Using sensitivity≥90%, the APRI cut-off in patients aged<30 years was also lower than patients aged≥30 years for significant fibrosis (0.2 vs 0.4) and cirrhosis (0.3 vs 0.5). Using specificity≥90%, the FIB-4 cut-off in patients aged<30 years was lower than that in patients aged≥30 years for significant fibrosis (1.2 vs 2.1) and cirrhosis (1.4 vs 2.6). Using sensitivity≥90%, the FIB-4 cut-off in patients aged<30 years was also lower than that in patients aged≥30 years for significant fibrosis (0.5 vs 0.8) and cirrhosis (0.8 vs 1.2). CONCLUSIONS: Evaluation of the diagnostic performances of APRI and FIB-4 should take age into consideration. Impact Journals LLC 2017-04-27 /pmc/articles/PMC5542225/ /pubmed/28514753 http://dx.doi.org/10.18632/oncotarget.17470 Text en Copyright: © 2017 Li et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Li, Qiang Lu, Chuan Li, Weixia Huang, Yuxian Chen, Liang Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B |
title | Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B |
title_full | Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B |
title_fullStr | Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B |
title_full_unstemmed | Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B |
title_short | Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B |
title_sort | impact of age on the diagnostic performances and cut-offs of apri and fib-4 for significant fibrosis and cirrhosis in chronic hepatitis b |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542225/ https://www.ncbi.nlm.nih.gov/pubmed/28514753 http://dx.doi.org/10.18632/oncotarget.17470 |
work_keys_str_mv | AT liqiang impactofageonthediagnosticperformancesandcutoffsofapriandfib4forsignificantfibrosisandcirrhosisinchronichepatitisb AT luchuan impactofageonthediagnosticperformancesandcutoffsofapriandfib4forsignificantfibrosisandcirrhosisinchronichepatitisb AT liweixia impactofageonthediagnosticperformancesandcutoffsofapriandfib4forsignificantfibrosisandcirrhosisinchronichepatitisb AT huangyuxian impactofageonthediagnosticperformancesandcutoffsofapriandfib4forsignificantfibrosisandcirrhosisinchronichepatitisb AT chenliang impactofageonthediagnosticperformancesandcutoffsofapriandfib4forsignificantfibrosisandcirrhosisinchronichepatitisb |